-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio publishes Phase 2 MINDFuL results for XPro in Alzheimer’s subgroup with inflammation

PUBT·05/15/2026 12:01:55
Listen to the news
INmune Bio publishes Phase 2 MINDFuL results for XPro in Alzheimer’s subgroup with inflammation
  • INmune Bio published Phase 2 MINDFuL trial results for XPro in mild Alzheimer’s disease in NPJ Dementia on May 15, 2026, with results already presented in the paper.
  • In a pre-specified subgroup selected for inflammatory markers, XPro showed broadly consistent signs of benefit across clinical measures and disease-related biomarkers over 24 weeks.
  • Safety profile appeared supportive, with no amyloid-related imaging abnormalities reported in the study.
  • Publication supports a strategy to focus future development on an inflammation-enriched patient population, positioning program for later-stage clinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150800PRIMZONEFULLFEED9720801) on May 15, 2026, and is solely responsible for the information contained therein.